Europe Cell Line Development Market size may exceed USD 2.1 billion by 2024: Graphical Research. According to the Graphical Research new growth forecast report titled “Europe Cell Line Development Market analysis based on Product, Source, Cell Line, Application, Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2018 - 2024�, estimated to exceed USD 2.1 billion by 2024. Growing disease burden across the globe is the key factor that will drive cell line development market growth. Rising demand for vaccines and monoclonal antibodies in treatment of cancer, autoimmune diseases and anti-inflammatory disease will fuel demand for cell line cultures. Developments in biotechnology industry, increasing healthcare expenditure coupled with growing adoption of technologically advanced products should accelerate the cell line development industry growth.
Technological advancements in cell line development products is another major contributor for cell line development business growth. Availability of automated screening methods, enriched medias, disposable equipment and improved expression systems for enhancing cell line development practices will foster market growth. However, stringent regulatory constraints may hamper the cell line development industry growth over the forecast timeframe. Reagents and media product segment accounted for largest market share of 53.6% in 2017 and is projected to show robust growth throughout the analysis period. Reagents and media form major component of cell culture procedures. Increasing usage of reagents and media in drug discovery, tissue engineering, and other research applications will accelerate the segmental growth over the analysis period. Browse key industry insights from this 2018 report Europe Cell Line Development Market in detail along with the table of contents at: https://bit.ly/2N4VHQC Mammalian cell cultures segment was valued at USD 650.8 million in 2017 and is estimated to show similar growth during the forecast period. The growth is attributable to increasing adoption of mammalian cell cultures for production of complex biotherapeutic proteins. Mammalian cell cultures are widely used in vaccine production for treatment of mumps, rubella and other diseases. Increasing acceptance of mammalian cell source to produce monoclonal antibodies will further boost the segmental growth. Recombinant cell line type segment is anticipated to grow at 12.5% CAGR during the forthcoming years. Advent of rDNA technology has drastically increased the demand for recombinant cell lines. Wide adoption of rDNA technology in production of enzymes, synthetic 1|Page